Leo International Precision Healthcare AG (LIPH) is building an active healthcare platform that unites AI-driven precision health assets across biotech, medtech, healthtech and healthcare services.
The integration of Renhe Biotech Pty Ltd, an Australian-based nutraceutical innovator, expands LIPH’s platform into the rapidly growing field of cellular health and longevity science. By combining scientifically formulated nutraceuticals with AI-enabled diagnostics and precision health technologies, LIPH continues to strengthen its multi-disciplinary healthcare platform.
Renhe Biotech focuses on the development of scientifically formulated nutraceuticals designed to support cellular health and metabolic resilience. The underlying formulations originate from proprietary research projects supported by Australian industry innovation programs and are protected through trade secret know-how. Production follows GMP (Good Manufacturing Practice) standards with scalability and global distribution in mind.
Renhe Biotech’s formulations leverage advances in NAD⁺ biology, a key area of research in cellular metabolism and healthy ageing. NAD⁺ plays a central role in DNA repair, mitochondrial metabolism and cellular stress response pathways. By supporting endogenous NAD⁺ homeostasis, these formulations are designed to contribute to cellular resilience, metabolic balance and overall wellbeing.
Learn more about LIPH: www.liphag.com
Learn more about Renhe Biotech: https://lnkd.in/drCwtsDH
